An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naive Prostate Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Pasireotide (Primary) ; Everolimus
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 14 Jul 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018 as per ClinicalTrials.gov record.
- 14 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.